Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.

Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.

Pivotal data set the stage for slightly delayed US accelerated approval filing.

But first it will need to identify the optimal dose in first-line small-cell lung cancer.

So far the data, with a Car-T Legend licensed to Novartis, lag antibody approaches.

Global data are in the same ballpark as Chinese results presented earlier this year.